Laura Gandolfi

Dr. Laura Gandolfi


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Life
Verified
Journal Article
Open access
PDF file
SCSara Cherri
Sara Cherri
LMLaura Melocchi
Laura Melocchi
LGLaura Gandolfi
Laura Gandolfi
GRGiulio Rossi
Giulio Rossi
Alberto ZaniboniAlberto Zaniboni
Alberto Zaniboni
In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as “untargetable”; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists.

22 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Paola ParentePaola Parente
Paola Parente
VAValentina Angerilli
Valentina Angerilli
FGFederica Grillo
Federica Grillo
MAMaria Raffaella Ambrosio
Maria Raffaella Ambrosio
FPFederica Petrelli
Federica Petrelli
Matteo FassanMatteo Fassan
Matteo Fassan
Introduction: Colorectal cancer (CRC) is the third most frequent malignancy and the second cause of cancer-related death worldwide. CRC is characterized by morphologic and biological heterogeneity, and molecular profiling is required to select appropriate treatment in the metastatic setting. Mutations in KRAS are detected in approximately 40% of CRCs, with prognostic and predictive value, and with the most frequent being p.G12D. Nonetheless, there are few data on the morphologic features in KRAS-mutated CRCs. Materials and Methods: We retrospectively collected clinicopathological features and molecular profiles of CRCs in a multicenter cohort. Results: A total of 2816 patients from 12 centers were included. KRAS mutation was found in 47.4% of cases; Gly12Asp was detected in 23.9%, with different mutation frequencies between centers. Clinicohistological features associated with Gly12Asp mutation included younger patient age (≤70 years of age), higher prevalence in males (58.6%), NOS histotype (87.1%), low pathologic grade (73.9%), high grade budding—Bd3 (43.8%), and tumoral lympho-vascular invasion (68.9%). Conclusions: Recent data have pinpointed the prognostic and predictive value of Gly12Asp mutation, and our results contribute to understanding its biology, with particular focus on peculiar clinicopathological features. Moreover, we found significant differences in pathology reports and assays for molecular profiling in different centers, which can affect a standardized therapeutic approach in CRC.